Baudax Bio Balance Sheet Health

Financial Health criteria checks 0/6

Baudax Bio has a total shareholder equity of $-1.2M and total debt of $5.2M, which brings its debt-to-equity ratio to -436.4%. Its total assets and total liabilities are $20.6M and $21.8M respectively.

Key information

-436.4%

Debt to equity ratio

US$5.23m

Debt

Interest coverage ration/a
CashUS$363.00k
Equity-US$1.20m
Total liabilitiesUS$21.78m
Total assetsUS$20.58m

Recent financial health updates

Recent updates

Baudax Bio stock down after pricing $6.2M equity offering

Aug 30

Baudax Bio to get US patent linked to pain drug Anjeso

Aug 22

Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M

Aug 11

Cosette Pharmaceuticals appoints Rick Casten as CFO

Jul 06

Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds

Sep 09

A First Look At Baudax Bio

May 30

Baudax Bio EPS misses by $0.08, misses on revenue

May 05

Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty

Apr 26

Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Feb 17
Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?

Baudax Bio EPS of $0.62

Nov 09

Baudax Bio: Why I'm Catching This Falling Knife

Nov 03

Financial Position Analysis

Short Term Liabilities: BXRX.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BXRX.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BXRX.Q has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BXRX.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BXRX.Q has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BXRX.Q has less than a year of cash runway if free cash flow continues to grow at historical rates of 15% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.